NIH R01 · 2025
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB
Pulmonary infections with Mycobacterium tuberculosis (M.tb) account for a staggering amount of morbidity and mortality worldwide. A highly effective vaccine able to prevent (i) active disease, (ii) relapse after chemotherapy, and (iii) reinfection, remains elusive even in the face of concerted global efforts. One obstacle hindering the comparison of vaccine candidates and their progression in the pipeline is a lack of consensus in the field on important immunological endpoints to include in preclinical studies and clinical trials. The research proposed here aims to leverage core models with a suboptimal drug treatment regimen to resolve differences in relapse rates with or without…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.